
|Articles|July 22, 2022
Daily Medication Pearl: Privigen Immune Globulin Intravenous (Human)
Author(s)Saro Arakelians, PharmD
Privigen is indicated for the treatment of primary humoral immunodeficiency, chronic immune thrombocytopenic purpura in patients 15 years of age and older, chronic inflammatory demyelinating polyneuropathy in adults.
Advertisement
Medication Pearl of the Day: Privigen Immune Globulin Intravenous (Human)
Indication: Privigen is an immune globulin intravenous (human), 10% liquid indicated for the treatment of primary humoral immunodeficiency, chronic immune thrombocytopenic purpura in patients 15 years of age and older, chronic inflammatory demyelinating polyneuropathy in adults.
Insight:
- Dosing: Dosing may vary from 0.5 mg/kg/min to 8 mg/kg/min
- Dosage forms: Privigen is a liquid solution containing 10% IgG (0.1 g/mL).
- Adverse events: The most common adverse reactions, observed in >5% of study subjects, were headache, fatigue, nausea, chills, vomiting, back pain, pain, elevated body temperature, abdominal pain, diarrhea, cough, stomach discomfort, chest pain, joint swelling/effusion, influenza-like illness, pharyngolaryngeal pain, urticaria, and dizziness. Serious adverse reactions were hypersensitivity, chills, fatigue, dizziness, and increased body temperature.
- Mechanism of action: Privigen supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against a wide variety of bacterial and viral agents. The mechanism of action has not been fully elucidated but may include immunomodulatory effects.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
NK3 as a Drug Target: From Scientific Discovery to Guideline-Recognized Therapy
2
Sonrotoclax Plus Zanubrutinib Produces Deep MRD Responses in Treatment-Naive CLL
3
Orforglipron Reduces Body Weight Up to 14% in Women at Every Stage of Menopause
4
New Evidence Positions Finerenone as Foundational Therapy Across the CKD Spectrum
5































































































































